Philippe Dro

Trained in industrial pharmacy and finance, Philippe initiated and executed several strategic transactions in various startups both in biotech and medtech. Prior to its acquisition by Merck (US), he served at Themis Bioscience as Board member and CBO, and before its acquisition by GSK (UK), he served at the vaccine developer GlycoVaxyn AG as CEO and member of the Supervisory Board.

Before that, he was leading Endoart S.A. (Switzerland), a medtech company, in the position of CEO and Chairman of the Board through a successful turnaround of the company leading to its acquisition by Allergan (US, NASDAQ: AGN). As member of the founding team, he worked at Axovan, a GPCR biotech which was acquired by Actelion (Switzerland, SWIX: ATLN) in 2003.

Prior to that, he worked at Novartis, SkyePharma and Antares Pharma in a number of managing functions. Philippe currently serves on the board of several biotech and medtech startups.